Formulation and characterization of an oily-based system for oral delivery of insulin

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 73, Issue 2, 2009, Pages 269-279

  Elsayed, Amani ^a   Remawi, Mayyas Al ^b   Qinna, Nidal ^b   Farouk, Asim ^a   Badwan, Adnan ^b  

^a UNIVERSITY OF GEZIRA   (Sudan)

^b JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY   (Jordan)

Author keywords

Insulin; Microemulsion; Nanoparticles; Oral drug delivery

Indexed keywords

CHITOSAN; ENZYME; GLUCOSE; NANOCARRIER; PLACEBO; RECOMBINANT HUMAN INSULIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG RESPONSE; DRUG STABILITY; DRUG STORAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; MALE; MICROEMULSION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE; STOMACH JUICE; STORAGE TEMPERATURE; STREPTOZOCIN DIABETES; ZETA POTENTIAL;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DIABETES MELLITUS, EXPERIMENTAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; EMULSIONS; GASTRIC JUICE; HYDROGEN-ION CONCENTRATION; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MOLECULAR WEIGHT; NANOPARTICLES; OILS; PROTEIN STABILITY; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; TEMPERATURE; TIME FACTORS;

EID: 70349303363     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2009.06.004     Document Type: Article

References (56)

1. Chien Y.W. Human insulin: basic sciences to therapeutic uses. Drug Dev. Ind. Pharm. 22 (1996) 753-789
2. Gomez-Perez F.J., and Rull J.A. Insulin therapy: current alternatives. Arch. Med. Res. 36 (2005) 258-272
3. Arbit E. The physiological rationale for oral insulin administration. Diabetes Tech. Therap. 6 (2004) 510-517
4. Carino G., and Mathiowitz E. Oral insulin delivery. Adv. Drug Del. Rev. 35 (1999) 249-257
5. Reis C., Neufeld R., Ribeiro A., and Veiga F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2 (2006) 53-65
6. Bilati U., Allemann E., and Doelker E. Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles. Eur. J. Pharm. Biopharm. 59 (2005) 375-388
7. Wada R., Hyon S.H., and Ikada Y. Lactic acid oligomer microspheres containing hydrophilic drugs. J. Pharm. Sci. 79 (1989) 919-924
8. Uchida T., Yagi A., Oda Y., Nakada Y., and Goto S. Instability of bovine insulin in poly (lactide-co-glycolide) (PLGA) microspheres. Chem. Pharm. Bull. 44 (1996) 235-236
9. Cruz T., Gaspar R., Donato A., and Lopes C. Interaction between polycyanoacrylate nanoparticles and peritoneal macrophages: MTT metabolism, NBT reduction and NO production. Pharm. Res. 14 (1997) 73-79
10. George M., and Abraham T. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan. J. Control. Release 114 (2006) 1-14
11. Roberts G.A.F. Chitin Chemistry (1992), The Mac Millan Press, London pp. 1-7
12. Ma Z., Lim T., and Lim L. Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats. Int. J. Pharm. 293 (2005) 271-280
13. Lin Y., Mi F., Chen C., Chang W., Peng S., Liang H., and Sung H. Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules 8 (2007) 146-152
14. Sarmento B., Martins S., Rebeiro A., Veiga F., Neufeld R., and Ferreira D. Development and comparison of different nanoparticulate polyelectrolyte complexes as insulin carriers. Int. J. Peptide Res. Therap. 12 (2006) 131-138
15. Mao S., Bakowsky U., Jintapattanakit A., and Kissel T. Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and insulin. J. Pharm. Sci. 95 (2006) 1035-1048
16. Sadeghi A., Dorkoosh F., Avadi M., Saadat P., Rafiee-Tehrani M., and Junginger H. Preparation, characterization and antibacterial activities of chitosan, N-trimethyl chitosan (TMC) and N-diethylmethyl chitosan (DEMC) nanoparticles loaded with insulin using both the ionotropic gelation and polyelectrolyte complexation methods. Int. J. Pharm. 355 (2008) 299-306
17. Sarciaux J.M., Acar L., and Sado P.A. Using microemulsion formulations for oral delivery of therapeutic peptides. Int. J. Pharm. 120 (1995) 127-136
18. Cilek A., Celebi N., Tirnaksiz F., and Tay A. A lecithin-based microemulsion of rh-insulin with aprotinin for oral administration: investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats. Int. J. Pharm. 298 (2005) 176-185
19. Kasaai M.R. Calculation of Mark-Houwink-Sakurada (MHS) equation viscometric constants for chitosan in any solvent-temperature system using experimental reported viscometric constants data. Carbohydr. Polym. 68 (2007) 477-488
20. Xu X., Fu Y., Hu H., Duan Y., and Zhang Z. Quantitative determination of insulin entrapment efficiency in triblock copolymeric nanoparticles by high-performance liquid chromatography. J. Pharm. Biomed. Anal. 41 (2006) 266-273
21. Lee M., Var F., Shin-ya Y., Kajiuchi T., and Yang J. Optimum conditions for the precipitation of chitosan oligomers with DP 5-7 in concentrated hydrochloric acid at low temperature. Process Biochem. 34 (1999) 493-500
22. Varum K., Ottoy M., and SmidsrØd O. Acid hydrolysis of chitosans. Carbohydr. Polym. 46 (2001) 89-98
23. A. Qandil, A. Obaidat, M. Ali, B. Al-Taani, B. Tashtoush, N. Al-Jbour, M. Al Remawi, K. Al-Sou'od, A. Badwan, Investigation of the interactions in complexes of low molecular weight chitosan with ibuprofen, J. Solution Chem., doi: 10.1007/s10953-009-9405-4 (published online 09 April 2009).
24. Berger J., Reist M., Mayer J., Felt O., and Gurny R. Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical application. Eur. J. Pharm. Biopharm. 57 (2004) 35-52
25. Sabnis S., and Block L. Chitosan as an enabling excipient for drug delivery systems. 1. Molecular modifications. Int. J. Biol. Macromol. 27 (2000) 181-186
26. Hejazi R., and Amiji M. Chitosan-based gastrointestinal delivery systems. J. Control. Release 89 (2003) 151-165
27. Kaarsholm N., Havelund S., and Hougaard P. Ionization behavior of native and mutant insulins: Pk perturbation of B13-Glu in aggregated species. Arch. Biochem. Biophy. 283 (1990) 496-502
28. Ma Z., Yeoh H., and Lim L. Formulation pH modulates the interaction of insulin with chitosan nanoparticles. J. Pharm. Sci. 91 (2002) 1396-1404
29. Xu Y., and Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int. J. Pharm. 250 (2003) 215-226
30. Zhu S., Qian F., Zhang Y., Tang C., and Yin C. Synthesis and characterization of PEG modified N-trimethylaminoethylmethacrylate chitosan nanoparticles. Eur. Polym. J. 43 (2007) 2244-2253
31. Qun G., and Ajun W. Effects of molecular weight, degree of acetylation and ionic strength on surface tension of chitosan in dilute solution. Carbohydr. Polym. 64 (2006) 29-36
32. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 185 (1999) 129-188
33. Chehin R., Thorolfsson M., and Knappskog P. Domain structure and stability of human phenylalanine hydroxylase inferred from infrared spectroscopy. FEBS Lett. 422 (1998) 225-230
34. McIntosh K., Charman W., and Charman S. The application of capillary electrophoresis for monitoring effects of excipients on protein conformation. J. Pharm. Biomed. Anal. 16 (1998) 1097-1105
35. Oliva A., Farina J., and LIabres M. Influence of temperature and shaking on stability of insulin preparations: degradation kinetics. Int. J. Pharm. 143 (1996) 163-170
36. Brange J., Havelund S., and Hougaard P. Chemical stability of insulin. 2. Formation of higher molecular weight transformation products during storage of pharmaceutical preparations. Pharm. Res. 9 (1992) 727-734
37. Brange J., Andersen L., Laursen E., Meyn G., and Rasmussen E. Toward understanding insulin fibrillation. J. Pharm. Sci. 86 (1997) 517-525
38. Jintapattanakit A., Junyaprasert V., Mao S., Sitterberg J., Bakowsky U., and Kissel T. Peroral delivery of insulin using chitosan derivatives: a comparative study of polyelectrolyte nanocomplexes and nanoparticles. Int. J. Pharm. 342 (2007) 240-249
39. Taluja A., and Bae Y. Role of a novel excipient poly (ethylene glycol)-b-poly (l-histidine) in retention of physical stability of insulin in aqueous solution. Pharm. Res. 24 (2007) 517-1526
40. Whitehead K., Karr N., and Mitragotri S. Safe and effective permeation enhancers for oral drug delivery. Pharm. Res. 25 (2008) 1782-1788
41. Cheng M., Wang J., Li Y., Liu X., Zhang X., Chen D., Zhou S., and Zhang Q. Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme. J. Control. Release 129 (2008) 41-48
42. Rieux A., Fievez V., Garinot M., Schneider Y., and Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116 (2006) 1-27
43. Lyons K., Charman W., Miller R., and Porter C. Factors limiting the oral bioavailability of N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) and enhancement of absorption in rats by delivery in a water-in-oil microemulsion. Int. J. Pharm. 199 (2000) 17-28
44. Watnasirichaikul S., Rades T., Tuker I., and Davies N. Effects of formulation variables on characteristics of poly (ethylcyanoacrylate) nanocapsules prepared from w/o microemulsions. Int. J. Pharm. 235 (2002) 237-246
45. Araujo L., Sheppard M., Lobenberg R., and Kreuter J. Uptake of PMMA nanoparticles from the gastrointestinal tract after oral administration to rats: modification of the body distribution after suspension in surfactant solutions and in oil vehicles. Int. J. Pharm. 176 (1999) 209-224
46. Koga K., Kusawake Y., Ito Y., Sugioka N., Shibata N., and Takada K. Enhancing mechanism of labrasol on intestinal membrane permeability of the hydrophilic drug gentamicin sulfate. Eur. J. Pharm. Biopharm. 64 (2006) 82-91
47. Chae S., Jang M., and Nah J. Influence of molecular weight on oral absorption of water soluble chitosans. J. Control. Release 102 (2005) 383-394
48. Porter C.J., Charman S.A., Humberstone A.J., and Charman W.N. Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion. J. Pharm. Sci. 85 (1996) 357-361
49. N. Furda, M. Wayzata, Non-absorbable lipid binder, US Patent 4,223,023,16, 1980.
50. Jorgensen L., Moeller E.H., Weert M., Nielsen H., and Frokjaer S. Preparing and evaluating delivery systems for proteins. Eur. J. Pharm. Sci. 29 (2006) 174-182
51. Sah H. Protein instability toward organic solvent/water emulsification: implications for protein microencapsulation into microspheres. PDAJ. Pharm. Sci. Technol. 53 (1999) 1-10
52. Damge C., Vranckx H., Balschmidt P., and Couvreur P. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci. 86 (1997) 1403-1409
53. Patel D., Ritschel W., Chalasani P., and Rao S. Biological activity of insulin in microemulsion in mice. J. Pharm. Sci. 80 (1991) 613-614
54. Deshpande A., Rhodes C.T., and Shah N.H. Controlled release drug delivery system for prolonged gastric residence: an overview. Drug Dev. Ind. Pharm. 22 (1996) 531-539
55. Moses A. Gastro retentive dosage forms. Crit. Rev. Ther. Drug Carrier Syst. 10 (1993) 143-195
56. Whitelind L., Fell J., Collete J., and Sharma H. An in vivo study demonstrating prolonged gastric retention. J. Control. Release 55 (1998) 3-12